In the sections that follow, we critically examine the emerging roles of RKIP and YY1 in the context of metabolic disease, highlight current knowledge gaps, and discuss potential therapeutic implications for obesity, T2D, and cardiovascular disorders. Here, YY1 is linked to metabolic disease.